Wen Dong, Fu Pengcheng, Shuai Geliu, Wang Yuebin, Yu Shengxin, Liu Huiquan, Wan Wei, Zou Junrong, Zou Xiaofeng
The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China.
Front Oncol. 2025 Jul 3;15:1622117. doi: 10.3389/fonc.2025.1622117. eCollection 2025.
Bladder cancer (BCa) is one of the most prevalent malignant tumors globally, particularly among men. According to data from the Global Cancer Research Agency, the annual incidence of BCa continues to rise, and its clinical features are complex, involving various molecular mechanisms and pathophysiological processes. Although existing treatments such as surgery, chemotherapy, and immunotherapy have improved patient prognosis to some extent, many individuals remain at risk for recurrence and metastasis. Therefore, there is an urgent need to explore new biomarkers and therapeutic targets to enhance the diagnostic and therapeutic efficacy of BCa. In recent years, RNA methylation, as an important post-transcriptional modification, has gradually attracted the attention of researchers. Among the methyltransferases, methyltransferase-like 3 (METTL3) is considered a key regulator, which is mainly responsible for the N6-methyladenosine (mA) modification of mRNA. More and more studies have shown that METTL3 not only plays an important role in normal physiological processes, but also is closely related to the occurrence and development of a variety of tumors. This review aims to systematically explore the role of METTL3 in BCa, including its biological function, expression characteristics, potential therapeutic targets, and prognosis related research progress. Through the in-depth analysis of METTL3, we hope to provide new ideas and directions for the early diagnosis, prognostic evaluation, and the development of novel treatment strategies for BCa.
膀胱癌（BCa）是全球最常见的恶性肿瘤之一，在男性中尤为常见。根据全球癌症研究机构的数据，BCa的年发病率持续上升，其临床特征复杂，涉及多种分子机制和病理生理过程。尽管手术、化疗和免疫疗法等现有治疗方法在一定程度上改善了患者的预后，但许多患者仍有复发和转移的风险。因此，迫切需要探索新的生物标志物和治疗靶点，以提高BCa的诊断和治疗效果。近年来，RNA甲基化作为一种重要的转录后修饰，逐渐引起了研究人员的关注。在甲基转移酶中，甲基转移酶样3（METTL3）被认为是关键调节因子，主要负责mRNA的N6-甲基腺苷（m6A）修饰。越来越多的研究表明，METTL3不仅在正常生理过程中发挥重要作用，而且与多种肿瘤的发生发展密切相关。本综述旨在系统探讨METTL3在BCa中的作用，包括其生物学功能、表达特征、潜在治疗靶点以及预后相关研究进展。通过对METTL3的深入分析，我们希望为BCa的早期诊断、预后评估以及新治疗策略的开发提供新的思路和方向。
